D.A. Davidson & CO. bought a new stake in Anavex Life Sciences Corp. (NASDAQ:AVXL – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 11,385 shares of the biotechnology company’s stock, valued at approximately $122,000.
Several other institutional investors and hedge funds have also bought and sold shares of the stock. Creative Planning grew its stake in Anavex Life Sciences by 54.2% in the third quarter. Creative Planning now owns 39,871 shares of the biotechnology company’s stock valued at $226,000 after purchasing an additional 14,010 shares in the last quarter. Private Advisor Group LLC boosted its holdings in shares of Anavex Life Sciences by 10.3% in the 3rd quarter. Private Advisor Group LLC now owns 47,413 shares of the biotechnology company’s stock valued at $269,000 after buying an additional 4,442 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Anavex Life Sciences by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company’s stock worth $93,000 after buying an additional 6,366 shares during the last quarter. Forum Financial Management LP bought a new stake in Anavex Life Sciences during the third quarter worth $200,000. Finally, Balentine LLC acquired a new stake in Anavex Life Sciences in the third quarter valued at $115,000. Institutional investors own 31.55% of the company’s stock.
Anavex Life Sciences Trading Down 2.7 %
AVXL opened at $7.85 on Friday. The stock’s fifty day simple moving average is $9.90 and its 200 day simple moving average is $7.83. Anavex Life Sciences Corp. has a 1-year low of $3.25 and a 1-year high of $14.44. The stock has a market cap of $667.72 million, a PE ratio of -14.27 and a beta of 0.69.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on AVXL. D. Boral Capital restated a “buy” rating and set a $46.00 price objective on shares of Anavex Life Sciences in a research note on Wednesday, February 12th. HC Wainwright reiterated a “buy” rating and set a $42.00 price target on shares of Anavex Life Sciences in a report on Tuesday, February 18th.
View Our Latest Analysis on Anavex Life Sciences
Anavex Life Sciences Profile
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
Featured Stories
- Five stocks we like better than Anavex Life Sciences
- How to Calculate Inflation Rate
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- What is diluted earnings per share (Diluted EPS)?
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- 3 REITs to Buy and Hold for the Long Term
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Want to see what other hedge funds are holding AVXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anavex Life Sciences Corp. (NASDAQ:AVXL – Free Report).
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.